Background: Bronchiolitis is the most common reason for hospital admission in infants, accounting for 20% of hospitalization at < 1 year of age. The recently discovered human meta pneumo-virus and other viruses like adenovirus, parainfluenza virus type-3, influenza virus and rhinovirus also cause bronchiolitis that is indistinguishable from respiratory syncytial virus (RSV) disease. It is more common in males, those who are not breast fed and living in crowded conditions. Objective: The aim of the work was to assess role of Ambroxol inhalation in treatment of Bronchiolitis. Patients and Methods: This randomized controlled clinical trial included a total of included 40 children with bronchiolitis, attending at Department of Pediatrics, Sohag General Hospital. They were randomly divided into two groups, the control group consisted of 20 cases who were given bronchodilators, inhaled or systemic steroids, antibiotics if needed, or supportive measures and oxygen supplementation if needed. The intervention group consisted of 20 cases who were treated with Ambroxol inhalation in addition to supportive measures mentioned above. Results: There was insignificant differences between two groups regarding the need of oxygen and duration of oxygen therapy (p-value 0.337, 0.536 respectively). In the current study, we found that there was insignificant differences between two groups regarding degree of RD on admission but after treatment there was significant improvement in interventional group with p-value <0.001. In the current study, we found that there was significant difference between two groups regarding length of hospital stay as in interventional group was lower than control (p-value 0.002). Conclusion: It could be concluded that Ambroxol gives a good improvement in cases with bronchiolitis and decreases hospital stay. Furthermore, Ambroxol is safe, cheap and easy to administer.